DHR Danaher Corporation

222.50USD-2.21%Mkt Cap: 160.10B USDP/E: 37.68

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, L…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap160.10B USD
Enterprise Value182.21B USD
Revenue (TTM)25.61B USD
Gross Profit14.52B USD
Net Income (TTM)3.61B USD
Revenue/Share36.27 USD
Last Price222.50 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees58.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)37.68
P/E (Forward)24.42
PEG1.30
EV/EBITDA22.07
EV/Revenue7.12
P/S6.25
P/B2.99
EPS (TTM)6.04 USD
EPS (Forward)9.32 USD
52W Range
160.9375% of range242.80
52W High242.80 USD
52W Low160.93 USD
Profitability
Gross Margin59.11%
Oper. Margin21.97%
EBITDA Margin32.24%
Profit Margin14.71%
ROE6.88%
ROA4.33%
ROIC5.90%
ROCE6.12%
Growth
Revenue Growth8.30%
Earnings Growth37.80%
Cash Flow & Leverage
Operating CF6.42B USD
CapEx (TTM)1.16B USD
FCF Margin18.53%
FCF Yield2.96%
Net Debt22.10B USD
Net Debt/EBITDA2.68
Net Debt/FCF4.66
Balance Sheet
Debt/Equity0.37
Current Ratio1.63
Quick Ratio1.19
Book Value/Sh76.23 USD
Cash/Share8.08 USD
Dividends
Fwd Div Rate1.60 USD
Trail. Div Rate1.52 USD
Div. Yield0.70%
5Y Avg Yield0.44%
Payout Ratio25.17%
Ex-Div DateSep 30, 2026
Pay DateOct 30, 2026
Splits
Last Split1128:1000
Split DateOct 2, 2023
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)259.90 USD
Upside (mean)+16.8%
Target Range220.00 USD – 310.00 USD
220.00+16.8% to mean310.00
# Analysts21
Ownership
Shares Out.703.53M
Float626.38M
Insiders10.83%
Institutions85.71%
Short Interest
Short Ratio1.9d
Short % Float1.33%
Short % Out.1.19%
Shares Short8.38M
Short (prev mo.)8.97M
Technical
SMA 50223.84 (-0.6%)
SMA 200201.12 (+10.6%)
Beta0.80
S&P 52W Chg12.00%
Avg Vol (30d)3.99M
Avg Vol (10d)3.49M
Technical Indicators
RSI (14)48.3
MACD1.1786
MACD Signal2.3867
MACD Hist.-1.2081
BB Upper238.20 USD
BB Middle231.60 USD
BB Lower225.01 USD
BB Width5.69%
ATR (14)5.917 USD
Vol Ratio (20d)1.18x

About Danaher (NYSE: DHR)

›

Danaher (NYSE: DHR) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 58,000 employees.

The shares were at 222.50 USD on 20 November 2026, up 3.6% over 52 weeks. Its 52-week range is 160.93 USD to 242.80 USD: the price is 8.4% below the high and 38.3% above the low.

At a market capitalisation of 160.10B USD, it trades at 37.7 times trailing earnings and 24.4 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 33.8, a premium of 12% for DHR. It pays a dividend yielding 0.70% (it pays out 25% of its earnings), against a median of 0.77% among the dividend payers in that peer group.

Danaher reports return on equity of 6.9%, an operating margin of 22.0% and revenue up 8.3% year over year.

Its debt exceeds its cash by 22.10B USD, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 259.90 USD is 16.8% above the current price. The next earnings report is expected on 27 January 2027.